5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
US11807638B2 · kind B2 · utility
1Cited by
13References
44Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2022 |
| Grant date | Nov 7, 2023 |
| Priority date | — |
| Expiry date | Dec 13, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.